The person in charge of Conacyt said that if the test is successful, the vaccine can be provided to Mexican health authorities for approval in December next year.
Mexico Start recruiting the first batch of volunteers Clinical Trials From his A vaccine against covid-19, Baptized as a homeland, reported this Tuesday that Maria Elena Alvarez Billera, General Manager of the National Council of Science and TechnologyConacyt).
Álvarez-Buylla said that the batches with the immunizing agent developed by the Mexican laboratory Avimex are now ready.
In order to conduct the first national trial, “from 90 to 100 healthy adults will be recruited Mexico CityHe said: “The result analysis will be carried out between this month and May in April.
If this and the following two phases of experiment They succeededÁlvarez-Buylla said the vaccine could be provided to Mexican health authority Cofepris for authorization in December.
The Mexican government has allocated 150 million pesos (US$7.4 million at the current exchange rate) for the development of this vaccine, which has been tested in mice and pigs so far.
The titers of antibodies produced by Mexico Biologics are similar to those of convalescent patients.
Mexico has 126 million inhabitants and has been immunized Monday 11.7 million peopleAnd have received Pfizer-BioNTech, AstraZeneca, SinoVac, Sputnik V and Cansino have produced 16.9 million vaccines.
When asked about the production capacity of the immune device, Álvarez-Buylla limited himself to saying that Avimex agreed to allocate two factories for the manufacturing process.
He pointed out that the laboratory has won praise for developing animal vaccines.
Regarding production costs, he pointed out that “the average price is 885% lower than the most expensive vaccine (sold on the market).”
The government of Lopez Obrador has invested approximately US$3.6 billion in the fight against the coronavirus.
Mexico andSEl The third largest country in the world Coronavirus has suffered the most in absolute numbers, with nearly 210,000 deaths.